Naporafenib

DRUG2 trials

Sponsors

Erasca, Inc.

Conditions

Advanced or Metastatic NRAS-mutant MelanomaAdvanced or Metastatic Solid Tumors

Phase 1

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Active, not recruitingNCT05907304

Erasca, Inc.Advanced or Metastatic Solid Tumors

Start: 2023-08-17End: 2026-12-01Updated: 2026-02-27

Phase 3

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Active, not recruitingNCT06346067

Erasca, Inc.Advanced or Metastatic NRAS-mutant Melanoma

Start: 2024-04-29End: 2028-12-01Updated: 2026-02-27

Related Papers

Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

JAMA Oncology2024-10-2446 citations

An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1).

Journal of Clinical Oncology2024-06-01